<DOC>
	<DOCNO>NCT02828540</DOCNO>
	<brief_summary>To assess efficacy evaluate safety HT047 patient acute ischemic stroke</brief_summary>
	<brief_title>Clinical Trial Assess Efficacy Evaluate Safety HT047 Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description>This clinical study design initiate treatment high low dose HT047 placebo subject acute ischemic stroke within 2 week onset disease evaluate neurological function recovery subject measure extent motor function recovery Week 12 treatment . Subjects must recent onset acute ischemic stroke confirm brain imaging . In term symptom ischemic stroke , patient motor function impairment FMA motor score ≤ 55 well neurological function impairment K-NIHSS score ≥ 4 ≤ 15 eligible study participation . A subject consider investigator appropriate study participation provide informed consent participate study . At baseline , subject randomize HT047 high dose group ( 2250 mg/day ) , HT047 low dose group ( 1500 mg/day ) , placebo group 1:1:1 ratio double blind fashion treat investigational product 12 week start next morning baseline three time day dose schedule , 3 tablet per dose . Since first-in-human trial HT047 , subject study visit Week 1 ( Day 7 ) participation laboratory test , ECG , chest x-ray . A one-month portion investigational product supply . During study treatment , subject visit hospital Weeks 1 , 4 , 8 , 12 . During Week 1 visit , test perform subject 's physical status check he/she send home . In subsequent visit , neurological function assessment drug exchange carry . At visit , study staff carefully check subject 's medication compliance verify accurate number remain dos counter . After 12 week study conduct show figure , Week 12 , laboratory test perform Week 1 repeat overall change subject 's status confirm study procedure end .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>1 . Adult age ≥ 19 ≤ 80 2 . Diagnosis acute ischemic stroke brain imaging within 14 day screen 3 . FMA motor score ≤ 55 arm leg weakness screen 4 . KNIHSS score ≥ 4 ≤ 15 screen 5 . Able communicate 6 . Voluntary write informed consent study participation 1 . Presence motor function impairment , cause previous stroke except acute ischemic stroke occur within 14 day screen ( A subject previous history stroke may participate he/she show motor function impairment KmRS score ≤1 ( 01 ) ) 2 . Diagnosis current treatment degenerative neurological disease , e.g. , Parkinson 's disease Alzheimer 's disease 3 . Current treatment amphetamine , selective serotonin reuptake inhibitor , antipsychotic 4 . Presence brain disease , brain tumor , traumatic brain damage , arteriovenous malformation , moyamoya disease , ischemic stroke cause disease 5 . Impaired ability walk upright due illness prior screen 6 . Unstable vital sign screen base judgment investigator e.g. , systolic blood pressure ≥ 170mmHg despite antihypertensive treatment symptom hyperthermia , tachycardia , hyperventilation 7 . Diagnosis liver diseases prior screening , hepatitis liver cirrhosis , current treatment diseases 8 . Continuous treatment potentially hepatotoxic drug e.g. , current treatment propylthiouracil , ketoconazole , isoniazid , valproic acid , phenytoin , etc . may induce acute hepatotoxicity 9 . Severe , New York Heart Association ( NYHA ) Class III high heart failure screen [ NYHA Classes heart failure ] Class I : patient limitation activity ; suffer symptom ordinary activity . Class II : patient slight , mild limitation activity ; comfortable rest mild exertion . Class III : patient marked limitation activity ; comfortable rest . Class IV : patient complete rest , confine bed chair ; physical activity bring . 10 . Diagnosis treatment cancer within 6 month screen presence recurrent metastatic cancer 11 . Treatment intake traditional oriental medicine ( herbal medicine ) health functional food contain potentially hepatotoxic plant , Germander ( Teucrium chamaedrys , Teucrium polium ) , toothed clubmoss ( Lycopodium serratum ) , celandine ( Chelidonium majus ) , within 4 week prior study participation 12 . Treatment intake traditional Korean medicine contain pueraria root and/or scutellaria root drug health functional food contain respective index component , i.e . puerarin baicalin , within 4 week prior study participation 13 . Hematologic finding follow ① Increased serum aspartate alanine aminotransferase ( AST/ALT ) level ≥ 1.5 x site specific upper limit normal laboratory test ② Decreased hemoglobin ( Hb ) level ( Hb &lt; 10 g/dl ) , decrease platelet ( PLT ) level ( PLT &lt; 100,000/mm3 ) , hematocrit ( Hct ) level &lt; 25 % whole blood count test . ③ Increased serum creatinine ( Cr ) level ( Cr &gt; 2.0 mg/dl ) laboratory test patient dialysis 14 . Pregnant lactate woman A woman childbearing potential participate study nonpregnancy confirm . Subjects must use double barrier method must surgically sterilize . 15 . Previous participation clinical study another drug within 3 month screen . A subject participate observational study involve drug treatment may participate study . 16 . Individuals consider investigator inadequate study participation due reason .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HT047</keyword>
	<keyword>Pueraria lobata</keyword>
	<keyword>Scutellaria baicalensis</keyword>
</DOC>